BioXcel Therapeutics (BTAI) Announces Quarterly Earnings Results
BioXcel Therapeutics (NASDAQ:BTAI) released its quarterly earnings results on Friday. The company reported ($0.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.05), MarketWatch Earnings reports.
BioXcel Therapeutics stock traded down $0.15 during trading hours on Friday, hitting $5.90. The company had a trading volume of 82,078 shares, compared to its average volume of 27,947. BioXcel Therapeutics has a one year low of $5.00 and a one year high of $14.79.
Several research analysts have weighed in on BTAI shares. Zacks Investment Research cut shares of BioXcel Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 9th. Canaccord Genuity reissued a “buy” rating and issued a $21.00 price target on shares of BioXcel Therapeutics in a report on Friday, August 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of BioXcel Therapeutics in a report on Wednesday, August 1st. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. BioXcel Therapeutics currently has an average rating of “Buy” and a consensus price target of $18.67.
TRADEMARK VIOLATION NOTICE: “BioXcel Therapeutics (BTAI) Announces Quarterly Earnings Results” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://www.thecerbatgem.com/2018/11/10/bioxcel-therapeutics-btai-announces-quarterly-earnings-results.html.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.
Featured Article: How accurate is the Rule of 72?
Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.